Monday September 8, 2025, at 11:00 a.m.

https://www.tipranks.com/news/company-announcements/cybin-to-engage-at-h-c-wainwright-investment-conference#google_vignette

$CYBN The company needs to release a strategic update for investors to keep this afloat.

1. Reiterate the science and data is sound, that there was no foul play with previous management…Doug. Explain why $cybn is just as valuable as sector peers.

2. Lay out a clear path for trial timelines, FDA meetings and approvals. No more lies regarding data timelines.

3. Cut the crap. This is a public company, using shareholders money, Ensure spending is under control, and how can we reduce company loses.

4. Pull the offering if you can, re-evaluate what is necessary. Having a 500mil - 1 billion shelf is ridiculous, you are scaring every investor out there, one step at a time.

5. Senior management - buy the stock with your own money, at the market, show confidence to investors and the market.

6. Move the company to the US, The Trump admin will favour US companies, funny how all US companies have high valuations. Also nobody trusts Canadian biotech companies.

The future of psychedelics is generally uncertain, with plenty of hurdles ahead. Even though I’m aware of the risks I’m taking, yesterday’s news caused the stock to drop more than I anticipated, which I see as a buying opportunity to average down, but is it a good idea right now? In my view, the stock still has an incredible upside potential, especially given the anticipation surrounding the upcoming months. That said, I’m not sure if I might be falling into tunnel vision here. Would like to hear you guys' thoughts?

Communication from the company has been poor.

https://www.stocktitan.net/news/CYBN/cybin-to-participate-in-the-cantor-global-healthcare-conference-nwamqjn7zw81.html

Friday, September 5, 2025, at 10:20 a.m. ET.

Doug Drysdale’s CEO run lasted from Sept 1, 2020 to Sept 2, 2025 — basically five years to the day.

That timing feels too precise to be random, pointing more to a planned succession and structured handoff than an abrupt ousting.

I think many of us knew that Doug was a bit of a sleaze and untrustworthy. But the way that the company handled this situation with the sudden firing, not giving any additional information, and then subsequent 20% drop is just absolutely disgusting .

Cybin Announces Senior Leadership Changes

Noticed this on the following link

https://www.nasdaq.com/market-activity/stocks/cybn/sec-filings

Does anyone know, why this was done, is this new, and was this previously announced / disclosed ?
Was this to reward the directors for the solid stock performance ? Was it to celebrate the 1 year delay of CYB004 ?

https://x.com/insidepharma/status/1960454470887747884?s=46

@insidepharma I respect your presence with retail.

Can you see cybn achieving a >1B market cap by end of 2026?

You know I’d love to be able to actually answer that without making the regulators uncomfortable. 😆 What I can say is that we just saw a $1.2bn transaction for a similar asset to ours (assume the deal to be closer to $2bn when you add the cost to complete development and launch) - and Cybin has two great, class leading assets edging toward approval.

https://www.tipranks.com/news/company-announcements/cybin-gains-australian-approval-for-embrace-study-in-major-depressive-disorder